NT5C2 and acute lymphoblastic leukemia: Another genetic determinant of thiopurine therapy came into focus after two GWAS studies concurrently and independently associated somatic mutations in the 5′-Nucleotidase, Cytosolic II (NT5C2) gene with relapse in childhood ALL patients [141,142].